Crossmark

Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1186/s12885-022-09326-5

Published Online: 2022-03-12

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ye, Feng

Bian, Lei

Wen, Jiahuai

Yu, Ping

Li, Na

Xie, Xiaoming

Wang, Xi https://orcid.org/0000-0001-7995-7961
Funding

Funding for this research was provided by:

Natural Science Foundation of Guangdong Province (2018A0303130285)
License Information

Text and Data Mining valid from 2022-03-12

Version of Record valid from 2022-03-12
More Information

Article History

Received: 19 April 2021

Accepted: 22 February 2022

First Online: 12 March 2022

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare to have no competing interest.

Document is current

Any future updates will be listed below